Johnson & Johnson (JNJ) EV/FCF Ratio: 34.18x
Is Johnson & Johnson’s EV/FCF ratio high or low?
Johnson & Johnson's EV/FCF ratio of 34.18x is 39% above its 5-year average of 24.59x, near the high end of its 5-year range (18.50x–34.96x).
As of Wednesday, June 17, 2026. 16.14% above its 12-month average of 29.43x.
JNJ EV/FCF Ratio Chart
JNJ Average EV/FCF Ratio Chart
JNJ Current vs Average EV/FCF Ratio Chart
JNJ EV/FCF Ratio Metrics
EV/FCF RATIO
34.18x
EV/FCF RATIO AVG TTM
29.43x
EV/FCF RATIO AVG 3Y
24.99x
EV/FCF RATIO AVG 5Y
24.59x
EV/FCF RATIO AVG 10Y
22.79x
EV/FCF RATIO AVG 15Y
21.14x
EV/FCF RATIO AVG 20Y
19.64x
CURRENT VS TTM AVG
+16.14%
CURRENT VS 3Y AVG
+36.77%
CURRENT VS 5Y AVG
+39.03%
CURRENT VS 10Y AVG
+50.00%
CURRENT VS 15Y AVG
+61.70%
CURRENT VS 20Y AVG
+73.99%
JNJ Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | $566.13B | 34.18x | 29.43x | 24.99x | 24.59x |
| Pfizer Inc. (PFE)vs › | $148.41B | 22.35x | 19.82x | 27.37x | 21.38x |
| Merck & Co., Inc. (MRK)vs › | $284.45B | 23.27x | 20.41x | 23.14x | 23.68x |
| AbbVie Inc. (ABBV)vs › | $393.06B | 21.96x | 23.64x | 20.07x | 17.83x |
| Eli Lilly and Company (LLY)vs › | $1.06T | 76.87x | 97.02x | 351.80x | 170.00x |
| Bristol-Myers Squibb Company (BMY)vs › | $114.19B | 12.53x | 10.46x | 11.37x | 12.30x |
Cash Flow Valuation Comparison
EV/FCF
34.2x
P/FCF
32.3x
FCF Yield
3.10%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
Johnson & Johnson EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Johnson & Johnson (JNJ)?
- The EV/FCF ratio for JNJ stock is 34.18x.
- Is Johnson & Johnson's EV/FCF ratio high or low?
- Johnson & Johnson's EV/FCF ratio of 34.18x is 39% above its 5-year average of 24.59x, near the high end of its 5-year range (18.50x–34.96x).
- What is the TTM average EV/FCF ratio for Johnson & Johnson (JNJ)?
- The TTM average EV/FCF ratio for JNJ stock is 29.43x.
- What is the 3Y average EV/FCF ratio for Johnson & Johnson (JNJ)?
- The 3Y average EV/FCF ratio for JNJ stock is 24.99x.
- What is the 5Y average EV/FCF ratio for Johnson & Johnson (JNJ)?
- The 5Y average EV/FCF ratio for JNJ stock is 24.59x.
- What is the 10Y average EV/FCF ratio for Johnson & Johnson (JNJ)?
- The 10Y average EV/FCF ratio for JNJ stock is 22.79x.
- What is the 15Y average EV/FCF ratio for Johnson & Johnson (JNJ)?
- The 15Y average EV/FCF ratio for JNJ stock is 21.14x.
- What is the 20Y average EV/FCF ratio for Johnson & Johnson (JNJ)?
- The 20Y average EV/FCF ratio for JNJ stock is 19.64x.
Johnson & Johnson EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-16 | 34.18x |
| 2026-06-15 | 34.25x |
| 2026-06-12 | 34.96x |
| 2026-06-11 | 34.61x |
| 2026-06-10 | 34.64x |
| 2026-06-09 | 34.43x |
| 2026-06-08 | 33.77x |
| 2026-06-05 | 33.85x |
| 2026-06-04 | 33.22x |
| 2026-06-03 | 32.54x |
| 2026-06-02 | 32.49x |
| 2026-06-01 | 32.58x |
| 2026-05-29 | 32.83x |
| 2026-05-28 | 33.58x |
| 2026-05-27 | 33.65x |
| 2026-05-26 | 33.49x |
| 2026-05-22 | 34.07x |
| 2026-05-21 | 33.71x |
| 2026-05-20 | 33.38x |
| 2026-05-19 | 33.47x |
| 2026-05-18 | 33.32x |
| 2026-05-15 | 33.02x |
| 2026-05-14 | 33.58x |
| 2026-05-13 | 33.53x |
| 2026-05-12 | 32.68x |
| 2026-05-11 | 32.29x |
| 2026-05-08 | 32.28x |
| 2026-05-07 | 32.44x |
| 2026-05-06 | 32.73x |
| 2026-05-05 | 32.86x |
| 2026-05-04 | 32.67x |
| 2026-05-01 | 33.08x |
| 2026-04-30 | 33.45x |
| 2026-04-29 | 33.11x |
| 2026-04-28 | 33.17x |
| 2026-04-27 | 32.83x |
| 2026-04-24 | 33.13x |
| 2026-04-23 | 33.56x |
| 2026-04-22 | 32.93x |
| 2026-04-21 | 29.41x |
| 2026-04-20 | 29.98x |
| 2026-04-17 | 30.41x |
| 2026-04-16 | 30.45x |
| 2026-04-15 | 30.96x |
| 2026-04-14 | 31.14x |
| 2026-04-13 | 30.88x |
| 2026-04-10 | 30.94x |
| 2026-04-09 | 31.29x |
| 2026-04-08 | 31.29x |
| 2026-04-07 | 30.93x |
| 2026-04-06 | 31.25x |
| 2026-04-02 | 31.50x |
| 2026-04-01 | 31.64x |
| 2026-03-31 | 31.68x |
| 2026-03-30 | 31.44x |
| 2026-03-27 | 31.18x |
| 2026-03-26 | 31.04x |
| 2026-03-25 | 31.12x |
| 2026-03-24 | 30.54x |
| 2026-03-23 | 30.56x |
| 2026-03-20 | 30.55x |
| 2026-03-19 | 30.83x |
| 2026-03-18 | 30.79x |
| 2026-03-17 | 30.89x |
| 2026-03-16 | 31.52x |
| 2026-03-13 | 31.32x |
| 2026-03-12 | 31.38x |
| 2026-03-11 | 31.50x |
| 2026-03-10 | 31.59x |
| 2026-03-09 | 31.45x |
| 2026-03-06 | 31.18x |
| 2026-03-05 | 31.08x |
| 2026-03-04 | 31.78x |
| 2026-03-03 | 31.96x |
| 2026-03-02 | 32.19x |
| 2026-02-27 | 32.17x |
| 2026-02-26 | 31.56x |
| 2026-02-25 | 31.77x |
| 2026-02-24 | 31.90x |
| 2026-02-23 | 31.85x |
| 2026-02-20 | 31.44x |
| 2026-02-19 | 31.98x |
| 2026-02-18 | 31.74x |
| 2026-02-17 | 31.54x |
| 2026-02-13 | 31.55x |
| 2026-02-12 | 31.69x |
| 2026-02-11 | 31.23x |
| 2026-02-10 | 31.79x |
| 2026-02-09 | 31.82x |
| 2026-02-06 | 32.00x |
| 2026-02-05 | 31.72x |
| 2026-02-04 | 31.29x |
| 2026-02-03 | 31.12x |
| 2026-02-02 | 30.82x |
| 2026-01-30 | 30.37x |
| 2026-01-29 | 30.38x |
| 2026-01-28 | 30.43x |
| 2026-01-27 | 30.02x |
| 2026-01-26 | 29.64x |
| 2026-01-23 | 29.47x |
| 2026-01-22 | 29.26x |
| 2026-01-21 | 29.20x |
| 2026-01-20 | 29.22x |
| 2026-01-16 | 29.28x |
| 2026-01-15 | 29.40x |
| 2026-01-14 | 29.27x |
| 2026-01-13 | 28.64x |
| 2026-01-12 | 28.14x |
| 2026-01-09 | 27.46x |
| 2026-01-08 | 27.64x |
| 2026-01-07 | 27.86x |
| 2026-01-06 | 27.51x |
| 2026-01-05 | 27.45x |
| 2026-01-02 | 27.84x |
| 2025-12-31 | 27.79x |
| 2025-12-30 | 27.78x |
| 2025-12-29 | 27.87x |
| 2025-12-26 | 27.88x |
| 2025-12-24 | 27.89x |
| 2025-12-23 | 27.64x |
| 2025-12-22 | 27.84x |
| 2025-12-19 | 27.72x |
| 2025-12-18 | 27.96x |
| 2025-12-17 | 28.22x |
| 2025-12-16 | 28.09x |
| 2025-12-15 | 28.71x |
| 2025-12-12 | 28.38x |
| 2025-12-11 | 28.18x |
| 2025-12-10 | 27.74x |
| 2025-12-09 | 26.90x |
| 2025-12-08 | 27.11x |
| 2025-12-05 | 27.15x |
| 2025-12-04 | 27.22x |
| 2025-12-03 | 27.58x |
| 2025-12-02 | 27.59x |
| 2025-12-01 | 27.58x |
| 2025-11-28 | 27.79x |
| 2025-11-26 | 27.87x |
| 2025-11-25 | 27.75x |
| 2025-11-24 | 27.67x |
| 2025-11-21 | 27.40x |
| 2025-11-20 | 27.30x |
| 2025-11-19 | 27.22x |
| 2025-11-18 | 26.90x |
| 2025-11-17 | 26.85x |
| 2025-11-14 | 26.39x |
| 2025-11-13 | 26.30x |
| 2025-11-12 | 26.19x |
| 2025-11-11 | 26.12x |
| 2025-11-10 | 25.43x |
| 2025-11-07 | 25.19x |
| 2025-11-06 | 25.25x |
| 2025-11-05 | 25.12x |
| 2025-11-04 | 25.23x |
| 2025-11-03 | 25.16x |
| 2025-10-31 | 25.49x |
| 2025-10-30 | 25.51x |
| 2025-10-29 | 25.20x |
| 2025-10-28 | 25.24x |
| 2025-10-27 | 25.67x |
| 2025-10-24 | 25.68x |
| 2025-10-23 | 25.95x |
| 2025-10-22 | 26.01x |
| 2025-10-21 | 30.25x |
| 2025-10-20 | 30.52x |
| 2025-10-17 | 30.44x |
| 2025-10-16 | 30.28x |
| 2025-10-15 | 30.14x |
| 2025-10-14 | 30.09x |
| 2025-10-13 | 30.10x |
| 2025-10-10 | 30.07x |
| 2025-10-09 | 30.13x |
| 2025-10-08 | 29.92x |
| 2025-10-07 | 29.80x |
| 2025-10-06 | 29.70x |
| 2025-10-03 | 29.77x |
| 2025-10-02 | 29.38x |
| 2025-10-01 | 29.39x |
| 2025-09-30 | 29.29x |
| 2025-09-29 | 28.73x |
| 2025-09-26 | 28.45x |
| 2025-09-25 | 28.16x |
| 2025-09-24 | 28.01x |
| 2025-09-23 | 27.99x |
| 2025-09-22 | 27.64x |
| 2025-09-19 | 27.93x |
| 2025-09-18 | 27.63x |
| 2025-09-17 | 28.08x |
| 2025-09-16 | 27.97x |
| 2025-09-15 | 28.11x |
| 2025-09-12 | 28.21x |
| 2025-09-11 | 28.27x |
| 2025-09-10 | 27.87x |
| 2025-09-09 | 28.05x |
| 2025-09-08 | 28.22x |
| 2025-09-05 | 28.26x |
| 2025-09-04 | 28.31x |
| 2025-09-03 | 28.20x |
| 2025-09-02 | 28.21x |
| 2025-08-29 | 28.08x |
| 2025-08-28 | 27.82x |
| 2025-08-27 | 28.02x |
| 2025-08-26 | 27.98x |
| 2025-08-25 | 28.26x |
| 2025-08-22 | 28.39x |
| 2025-08-21 | 28.34x |
| 2025-08-20 | 28.32x |
| 2025-08-19 | 28.17x |
| 2025-08-18 | 27.94x |
| 2025-08-15 | 28.00x |
| 2025-08-14 | 27.72x |
| 2025-08-13 | 27.67x |
| 2025-08-12 | 27.43x |
| 2025-08-11 | 27.58x |
| 2025-08-08 | 27.51x |
| 2025-08-07 | 27.25x |
| 2025-08-06 | 27.11x |
| 2025-08-05 | 27.13x |
| 2025-08-04 | 27.17x |
| 2025-08-01 | 26.63x |
| 2025-07-31 | 26.24x |
| 2025-07-30 | 26.62x |
| 2025-07-29 | 26.74x |
| 2025-07-28 | 26.46x |
| 2025-07-25 | 26.77x |
| 2025-07-24 | 26.96x |
| 2025-07-23 | 22.79x |
| 2025-07-22 | 22.64x |
| 2025-07-21 | 22.17x |
| 2025-07-18 | 22.09x |
| 2025-07-17 | 21.99x |
| 2025-07-16 | 22.23x |
| 2025-07-15 | 20.97x |
| 2025-07-14 | 21.19x |
| 2025-07-11 | 21.20x |
| 2025-07-10 | 21.30x |
| 2025-07-09 | 21.12x |
| 2025-07-08 | 21.06x |
| 2025-07-07 | 20.99x |
| 2025-07-03 | 21.08x |
| 2025-07-02 | 21.03x |
| 2025-07-01 | 21.07x |
| 2025-06-30 | 20.66x |
| 2025-06-27 | 20.61x |
| 2025-06-26 | 20.56x |
| 2025-06-25 | 20.60x |
| 2025-06-24 | 20.59x |
| 2025-06-23 | 20.47x |
| 2025-06-20 | 20.27x |
| 2025-06-18 | 20.40x |
| 2025-06-17 | 20.61x |
| 2025-06-16 | 20.98x |
| 2025-06-13 | 21.23x |
| 2025-06-12 | 21.17x |
| 2025-06-11 | 20.99x |
| 2025-06-10 | 21.14x |
| 2025-06-09 | 20.98x |
| 2025-06-06 | 20.96x |
| 2025-06-05 | 20.78x |
| 2025-06-04 | 20.72x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato